Program Description
Oncology pharmacists play a crucial role in treating patients with EGFR-positive metastatic non-small cell lung cancer (mNSCLC). However, the complexities of sequencing targeted therapies in EGFR-positive mNSCLC present significant challenges, especially as many patients experience resistance to treatment with EGFR-tyrosine kinase inhibitors. Limited knowledge about the implications of EGFR mutations on treatment decision-making can contribute to suboptimal treatment response, and oncology pharmacists must be proficient in interpreting and applying biomarker testing results for informed therapeutic decisions to achieve clinical benefit. Oncology pharmacists must also manage adverse effects associated with EGFR-targeted therapies, monitoring patients to ensure treatment efficacy and safety. This session will equip oncology pharmacists with updated guidance and clinical evidence to support informed decision-making about therapy sequencing, managing resistance mutations, and addressing individual patient factors in EGFR-positive mNSCLC. Best practices for therapeutic sequencing and adverse effect management will be highlighted through interactive patient case discussions led by the expert faculty panel.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 16, 2025
Expiration date: July 16, 2026
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the role of various activating and resistance mutations in guiding therapeutic decisions for patients with EGFR-positive metastatic non-small cell lung cancer (mNSCLC)
- Apply updated clinical evidence, guidelines, and individualized patient factors to personalize treatment plans for EGFR-positive mNSCLC
- Demonstrate effective strategies for preventing and managing treatment-related adverse effects of EGFR-targeted agents to improve tolerability and efficacy in mNSCLC